A Pilot Study to Evaluate the Efficacy and Safety of Secukinumab in the Treatment of Moderate to Severe Atopic Dermatitis
Phase of Trial: Phase II
Latest Information Update: 18 Apr 2017
At a glance
- Drugs Secukinumab (Primary)
- Indications Atopic dermatitis
- Focus Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 11 Apr 2017 Planned End Date changed from 1 Dec 2017 to 1 Apr 2018.
- 11 Apr 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Apr 2018.